Methyclothiazide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Oedema 2.5-5 mg once daily in the morning. Max: 10 mg/day. HTN 2.5-5 mg once daily, either alone or w/ other antihypertensives.
Dosage Details
Oral
Oedema
Adult: 2.5-5 mg once daily in the morning. Max: 10 mg once daily.

Oral
Hypertension
Adult: 2.5-5 mg once daily, either alone or w/ other antihypertensives.
Contraindications
Hypersensitivity to sulfonamide-derived drugs, anuria.
Special Precautions
Patient w/ fluid and electrolyte disturbances, gout, DM, hypercholesterolaemia, parathyroid disease, history of allergy and bronchial asthma. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Headache, cramping, weakness, orthostatic hypotension, pancreatitis, jaundice, sialadenitis, vomiting, diarrhoea, nausea, gastric irritation, constipation, anorexia, aplastic anaemia, haemolytic anaemia, agranulocytosis, leukopenia, thrombocytopenia, anaphylactic reactions, necrotising angiitis, Stevens-Johnson syndrome, resp distress, fever, purpura, urticaria, rash, photosensitivity, hyperglycemia, hyperuricemia, electrolyte imbalance, vertigo, dizziness, paraesthesia, muscle spasm, restlessness, transient blurred vision, xanthopsia, glycosuria.
MonitoringParameters
Assess wt, input and output reports daily to determine fluid loss, BP, serum electrolytes, BUN, creatinine.
Overdosage
Symptoms: Electrolyte imbalance and signs of K deficiency (e.g. confusion, dizziness, muscular weakness, GI disturbances). Management: General supportive measures including replacement of fluids and electrolytes.
Drug Interactions
Increased risk of lithium toxicity. Hypokalaemia may develop during concomitant use of steroids or ACTH. Insulin requirement in DM patients may be altered. Decreased arterial responsiveness to norepinephrine. Increased responsiveness to tubocurarine. Potentiation of orthostatic hypotension by barbiturates or narcotics.
Food Interaction
Avoid alcohol as it may potentiate orthostatic hypotension.
Lab Interference
May interfere w/ tests for parathyroid function. May decrease serum protein-bound iodine (PBI) levels w/o signs of thyroid disturbance.
Action
Description: Methyclothiazide inhibits Na reabsorption in the distal tubules causing increased excretion of Na and water, as well as K and hydrogen ions.
Onset: Approx 2 hr.
Duration: ≥24 hr.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: 6 hr.
Distribution: Crosses the placenta and excreted in breast milk.
Excretion: Via urine as unchanged drug.
Storage
Store between 20-25°C. Protect from light and moisture.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Methyclothiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in